Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Taxane Chemotherapy (Second-Line)

Cabazitaxel

Brand names: Jevtana

Cabazitaxel is a taxane cytotoxic chemotherapy agent used, with prednisolone, for metastatic castration-resistant prostate cancer previously treated with docetaxel.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds tubulin and stabilises microtubules, preventing their depolymerisation and thereby arresting cell division and inducing tumour cell death.

Prescribing in practice

  • Causes severe, potentially fatal neutropenia and febrile neutropenia; blood counts must be adequate before each cycle and growth-factor support considered in high-risk patients.
  • Premedication with an antihistamine, corticosteroid and H2 antagonist is required to reduce hypersensitivity reactions.
  • Administer only under specialist oncology supervision with management plans for severe diarrhoea and myelosuppression.

Monitoring

Monitor full blood count before each cycle, and watch for fever, diarrhoea and hypersensitivity reactions during treatment.

Counselling the patient

  • Seek urgent medical attention for fever, sore throat or signs of infection.
  • Report severe or persistent diarrhoea, which can cause dangerous dehydration.

Evidence & guidelines

Efficacy in docetaxel-pretreated castration-resistant prostate cancer was shown in the TROPIC trial and is reflected in NICE guidance.

Reference: NICE TA391 (Cabazitaxel for mCRPC); TROPIC Trial; CARD Trial; EAU Guidelines 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways